Cutler Group LP Vericel Corp Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 09, 2019	SELL	$15.01 - $18.89 $96,064 - $120,896	-6,400 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$16.23 - $20.29 $56,805 - $71,015	3,500 Added 120.69%	6,400 $112,000
Q4 2018 Feb 05, 2019	BUY	$10.77 - $18.44 $26,925 - $46,100	2,500 Added 625.0%	2,900 $50,000
Q2 2018 Aug 10, 2018	SELL	$9.6 - $14.6 $13,440 - $20,440	-1,400 Reduced 77.78%	400 $3,000
Q1 2018 May 11, 2018	SELL	$5.7 - $12.3 $5 - $12	-1 Reduced 0.06%	1,800 $17,000
Q4 2017 Jan 17, 2018	SELL	$3.65 - $5.98 $1,456 - $2,386	-399 Reduced 18.14%	1,801 $9,000
Q3 2017 Oct 17, 2017	BUY	$3.0 - $6.0 $6,600 - $13,200	2,200	2,200 $13,000

276

48.4M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.79B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.